Resource Type: Data Analysis

Almost half of clonoSEQ-tested patients receive the Clonality (ID) test using a fresh sample.

By

The type of specimen used for clonoSEQ MRD testing varies based on the patient’s diagnosis.

By

Patients are receiving longer-term MRD monitoring with clonoSEQ.

By

Nearly half of all patients who receive clonoSEQ MRD testing are monitored more frequently than once per year.

By

The time from Clonality (ID) test to first Tracking MRD test can span a longer time frame for patients with myeloma.

By

The time from Clonality (ID) test to first Tracking (MRD) test is usually within 3 months for patients with ALL.

By

The demographics of clonoSEQ-tested patients are consistent with overall disease demographics.

By

    Opt-in to receive future email communications regarding clonoSEQ

      

    I'm interested in:


    How did you learn about clonoSEQ?

    By checking the “I agree” box, you agree we can send you information about clonoSEQ (you’ll have the option to easily unsubscribe any time) and that you are 18 years of age or older.

    I am a registered user, please take me to the Diagnostic Portal.

    Log In

    I am a new user and need to request a new account

    Request Account

    Please select your location to continue:

    United States Outside the U.S.